Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance.
about
P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A reviewDesign and synthesis of human ABCB1 (P-glycoprotein) inhibitors by peptide coupling of diverse chemical scaffolds on carboxyl and amino termini of (S)-valine-derived thiazole amino acid.Docking applied to the prediction of the affinity of compounds to P-glycoproteinParameters of Reserpine Analogs That Induce MSH2/MSH6-Dependent Cytotoxic ResponseExploring the P-glycoprotein binding cavity with polyoxyethylene alkyl ethers.Computational and synthetic studies towards improving rescinnamine as an inducer of MSH2-dependent apoptosis in cancer treatmentCorrelation between rhodamine 123 accumulation and azole sensitivity in Candida species: possible role for drug efflux in drug resistance.Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators.Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cellsMultidrug resistance (mdr) genes in human cancer.Multidrug resistance: a novel class of membrane-associated transport proteins is identified.p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agentsTotal synthesis of ningalin DFuture directions for drug transporter modelling.From delocalized lipophilic cations to hypoxia: blocking tumor cell mitochondrial function leads to therapeutic gain with glycolytic inhibitors.P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans.P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake.Structure-activity relationships and in silico models of P-glycoprotein (ABCB1) inhibitors.Advances in plant-based inhibitors of P-glycoprotein.Reversion of multidrug resistance in a chemoresistant human breast cancer cell line by β-elemene.Neonatal domoic acid alters in vivo binding of [(11)C]yohimbine to α2-adrenoceptors in adult rat brain.Reversal effects of components from the fruits of Illicium simonsii on human Adriamycin-resistant MCF-7 and 5-fluorouracil-resistant Bel7402 cells.Reversal of multidrug resistance by guggulsterone in drug-resistant MCF-7 cell lines.Polyaromatic alkaloids from marine invertebrates as cytotoxic compounds and inhibitors of multidrug resistance caused by P-glycoprotein.The use of 99mTc-MIBI scanning in multiple myeloma.Modulation of P-glycoprotein activity by cannabinoid molecules in HK-2 renal cells.Photoaffinity labeling of P-glycoprotein in multidrug-resistant cells.The relative importance of passive and P-glycoprotein mediated anthracycline efflux from multidrug-resistant cells.Partial inhibition of multidrug resistance by safingol is independent of modulation of P-glycoprotein substrate activities and correlated with inhibition of protein kinase C.Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells.Ligand and structure-based classification models for prediction of P-glycoprotein inhibitors.Prediction of biliary excretion in rats and humans using molecular weight and quantitative structure-pharmacokinetic relationships.Linear and cyclic peptides as substrates and modulators of P-glycoprotein: peptide binding and effects on drug transport and accumulationSelective inhibition of MDR1 P-glycoprotein-mediated transport by the acridone carboxamide derivative GG918.Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells.Neither lipophilicity nor membrane-perturbing potency of phenothiazine maleates correlate with the ability to inhibit P-glycoprotein transport activity.Radioligand binding analysis of α 2 adrenoceptors with [11C]yohimbine in brain in vivo: Extended Inhibition Plot correction for plasma protein binding.Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells.Do adsorbed drugs onto P-glycoprotein influence its efflux capability?Long-lasting accumulation of vinblastine in inostamycin-treated multidrug-resistant KB cells.
P2860
Q27024260-EE49ECC8-091B-47DE-8B3E-5D000B3EB147Q33654580-47803EA3-8E4A-4607-9010-3CCAB9949759Q33757813-132A0355-F4E7-4E72-B4B4-A5893425858FQ34159515-EC041B0B-0DBE-41A0-B51A-17DE55EA72DFQ34388732-D3A7346E-6A22-4B3D-9887-E6EBF5BCEEDBQ34626771-E194E9EC-0DD6-47AB-92AB-8492C9E4DDA5Q35122459-90D21D24-6C25-4EC4-982B-C267EA31F1FDQ35644350-2A0A54EF-F095-4EE2-A5BE-CB8B919E8688Q36134814-C8F3A006-3C80-4CBE-9BE5-7F918387EBC3Q36495579-8AB41679-AC79-4C83-B11E-5F6C5E8262EFQ36527076-C2E55867-BF01-402E-B891-5900E16BE8A3Q36605767-867B24BD-357F-49A5-8709-9526E345DDCCQ36784825-E67846F7-4736-44C7-B83F-80020E7A5C8EQ36985072-CB331C98-7B2F-46D5-9F3D-5BBCF10170A7Q37346228-4959D637-255B-492B-B2B4-928BB996CF21Q37626608-D2947E33-8E56-455D-B7EF-65C9B02E878DQ37735490-5D8805C4-837A-4CBF-91FA-C3897DBC88ACQ38101682-B33AD2BF-AFEF-4CFC-BE20-ADB41D5A1835Q38756967-DE89341A-867A-4C52-A834-F47F07F3E8FBQ39351259-7D818637-299A-42BB-8CFF-43C27476AFAEQ39456703-9AE718C1-2E12-4038-823C-B3C2C4D14D26Q39466977-EF2443F7-FDD6-4913-BCE2-599D4C3345FEQ39599792-274C4295-9C3E-43E1-9741-FD83FEACF552Q39998933-3A597117-3783-48C6-85CF-0E85EC56D17DQ40073883-7F718394-FCAC-4987-BAB2-F9E3E7E73027Q40277195-CB891B7A-3C06-486C-8061-9835665A0410Q40707964-15DD3037-68B1-46CF-978B-341DA76304ABQ40903421-D585E7FB-E489-4679-A0AF-297BC788FF7BQ41272448-45AEB43A-83CE-4AFD-AA6C-3B6F52601333Q41472858-66223E9D-D3EC-45C8-B476-D4047063E9E2Q41771553-81B590D4-89B7-456A-B72B-365FA24433A9Q41846225-F19A22CD-1767-43BB-B5B3-8F6C7C87EF84Q41907216-DE9281E1-4519-4508-9273-4D3A96C623EDQ42029087-C5BF7B9B-CFF0-4A1F-B67D-6F9D73FD7F5FQ42390506-70F2C70C-EED0-4850-822C-8995DE4A72C5Q44440276-CE1F6705-25FC-406A-B281-27146E5EC2C4Q47107655-C416508C-0687-4556-914A-7A1982254794Q51479929-10FF1A92-9E63-432B-88D6-1E301DCD72E1Q53595926-A13AC752-7D23-4BC9-8454-E7E6ABFF70AFQ54964334-7E579F72-3073-459F-A246-E861A5290F03
P2860
Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance.
description
1989 nî lūn-bûn
@nan
1989 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Essential features of the P-gl ...... modulate multidrug resistance.
@ast
Essential features of the P-gl ...... modulate multidrug resistance.
@en
Essential features of the P-gl ...... modulate multidrug resistance.
@nl
type
label
Essential features of the P-gl ...... modulate multidrug resistance.
@ast
Essential features of the P-gl ...... modulate multidrug resistance.
@en
Essential features of the P-gl ...... modulate multidrug resistance.
@nl
prefLabel
Essential features of the P-gl ...... modulate multidrug resistance.
@ast
Essential features of the P-gl ...... modulate multidrug resistance.
@en
Essential features of the P-gl ...... modulate multidrug resistance.
@nl
P2093
P2860
P356
P1476
Essential features of the P-gl ...... modulate multidrug resistance.
@en
P2093
P2860
P304
P356
10.1073/PNAS.86.13.5128
P407
P577
1989-07-01T00:00:00Z